The gene sequencing start up is not for sale (even for $5.7 billion)

15 Mar

Molecular medicine.

BioCamp participants getting insights into the...

BioCamp participants getting insights into the pharmaceutical industry (Photo credit: Novartis AG)

English: DNA replication or DNA synthesis is t...

Image via Wikipedia

Building 32 on the Genentech headquarters camp...

Image via Wikipedia

A parking sign on the Genentech headquarters c...

Image via Wikipedia

Roche implements a strategy to treat the chronic diseases at a molecular level. To do so it has to acquire the start-us that possesses the relevant knowledge. Molecular engineering, including the DNA molecule, is far from the usual chemistry to which the traditional drugs makers are accustomed. In order to complete this goal the Swiss Drug maker leads a policy of takeover bid for American High Tech Companies settled in California (e.g. San Diego, for Illumina, Inc. or San Francisco for Genentech, Inc.) or Arizona ( Tucson for Ventana Medical Systems, Inc.). For now, Illumina has not yet been bought by Roche but it would be only a matter of time according to financial analysts. From a medical point of view Genentech makes human antibodies which are human molecules targeting the antigens located on the cell membrane. The action of such antibodies results in various therapeutic effects in chronic diseases. But unfortunately, as soon as the treatment is stopped the symptoms reappears. Ventana makes also antibodies, but for diagnosis purpose. The molecular diagnostic tests it produces aims to classified cancer cells in order to refine the individual prognosis of the disease (and to indicate the targeted treatment that is needed). More deeper in the molecular level, clerly in the heart of the cell and the identity of the person, Illumina discovered the method to sequence the genotype of the patient. It’s of the greatest importance for Roche to buy this start-up because in the future, treatment will be prescribed not only with regard of the condition diagnosed by the Doctors but also relatively to the genome of the patient.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 91 other followers

%d bloggers like this: